Evidence map›Paper›PMID 25799011›Full record

ArticlePloS one2015

Vitamin D metabolic pathway genes and pancreatic cancer risk.

Hannah Arem, Kai Yu, Xiaoqin Xiong, Kristin Moy, Neal D Freedman, Susan T Mayne, Demetrius Albanes, Alan A Arslan, Melissa Austin, William R Bamlet and 42 more

Erratum issuedOpen access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 5 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 5 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Bioinformatics for The Prognostic Value and Function of Cubilin (CUBN) in Colorectal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

52 authors at 20 institutions in 6 countries.

Hannah AremDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Kai YuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Xiaoqin XiongInformation Management Systems, Inc., Calverton, Maryland, United States of America.
Kristin MoyDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Neal D FreedmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Susan T MayneYale School of Public Health/Yale Cancer Center, New Haven, Connecticut, United States of America.
Demetrius AlbanesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Alan A ArslanDepartments of Population Health, Obstetrics and Gynecology (Obs/Gyn) and Environmental Medicine, New York University, New York, New York, United States of America.
Melissa AustinDepartment of Epidemiology, University of Washington, Seattle, Washington, United States of America.
William R BamletDepartment of Epidemiology, Mayo Clinic, Rochester, Minnesota, United States of America.
Laura Beane-FreemanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Paige BracciDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.
Federico CanzianDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Michelle CotterchioDalla Lana School of Public Health, University of Toronto; Prevention and Cancer Control, Cancer Care Ontario Toronto, Ontario, Canada.
Eric J DuellCatalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain.
Steve GallingerSamuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
Graham G GilesCancer Epidemiology Centre, Cancer Council Victoria and Centre for MEGA Epidemiology, School of Population Health, the University of Melbourne, Melbourne, Australia.
Michael GogginsDepartments of Oncology, Pathology and Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.
Phyllis J GoodmanCleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, Ohio, United States of America.
Patricia HartgeDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Manal HassanDepartment of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Kathy HelzlsouerMD Mercy, Baltimore, Maryland, United States of America.
Brian HendersonDepartment of Preventative Medicine, School of Medicine, University of Southern California, Los Angeles, California, United States of America.
Elizabeth A HollyDepartment of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, United States of America.
Robert HooverDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Eric J JacobsEpidemiology Research Program, American Cancer Society, Atlanta, Georgia, United States of America.
Aruna KamineniGroupHealth Research Institute, Seattle, Washington, United States of America.
Alison KleinMD Mercy, Baltimore, Maryland, United States of America.
Eric KleinCleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, Ohio, United States of America.
Laurence N KolonelUniversity of Hawaii Cancer Center, Manoa, Hawaii, United States of America.
Donghui LiDepartment of Gastrointestinal Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States of America.
Núria MalatsMolecular Pathology Program, Spanish National Cancer Research Center, Madrid, Spain.
Satu MännistöNational Institute for Health and Welfare, Department of Chronic Disease Prevention, Helsinki, Finland.
Marjorie L McCulloughEpidemiology Research Program, American Cancer Society, Atlanta, Georgia, United States of America.
Sara H OlsonDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Irene OrlowDepartment of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America.
Ulrike PetersCleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, Ohio, United States of America.
Gloria M PetersenDepartment of Epidemiology, Mayo Clinic, Rochester, Minnesota, United States of America.
Miquel PortaHospital del Mar Institute of Medical Research (IMIM), and School of Medicine, Barcelona Spain.
Gianluca SeveriCancer Epidemiology Centre, Cancer Council Victoria and Centre for MEGA Epidemiology, School of Population Health, the University of Melbourne, Melbourne, Australia.
Xiao-Ou ShuDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee, United States of America.
Kala VisvanathanMD Mercy, Baltimore, Maryland, United States of America.
Emily WhiteCleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, Ohio, United States of America.
Herbert YuUniversity of Hawaii Cancer Center, Manoa, Hawaii, United States of America.
Anne Zeleniuch-JacquotteDepartments of Population Health, Obstetrics and Gynecology (Obs/Gyn) and Environmental Medicine, New York University, New York, New York, United States of America.
Wei ZhengDivision of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, and Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee, United States of America.
Geoffrey S TobiasDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Dennis MaederCancer Genomics Research Laboratory, National Cancer Institute, Division of Cancer Epidemiology and Genetics, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.
Michelle BrotzmanWestat, Rockville, Maryland, United States of America.
Harvey RischYale School of Public Health/Yale Cancer Center, New Haven, Connecticut, United States of America.
Joshua N SampsonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Rachael Z Stolzenberg-SolomonDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America.
Division of Cancer Epidemiology and GeneticsNational Cancer Institute · USCleveland Clinic · USMercy Medical Center · USAmerican Cancer Society · USCancer Council Victoria · AUMemorial Sloan Kettering Cancer Center · USNew York University · USThe University of Texas MD Anderson Cancer Center · USUniversity of California, San Francisco · USUniversity of Hawaii Cancer CenterVanderbilt University · USYale Cancer Center · USCancer Care Ontario · CAFinnish Institute for Health and Welfare · FIHeidelberg University · DEInformation Management Services · USInstitut Català d'Oncologia · ESJohns Hopkins University · USKaiser Permanente Washington Health Research Institute · US

Funding

SWOG Foreign AccrualsU10CA037429 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI BLANKE, CHARLES D., MEYSKENS, FRANK L. · 1985 to 2014
$205.2M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Tissue CoreP50CA102701 · NCI · MAYO CLINIC ROCHESTER · PI COHEN, PETER A · 2004 to 2018
$32.7M
Whole Genome Scan in the Pancreatic Cancer Cohort Consortium (PanScan)ZIACP010193 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI STOLZENBERG-SOLOMON, RACHAEL · 2009 to 2025
$9.5M
Shanghai Womens Health StudyUM1CA182910 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ZHENG, WEI · 2014 to 2018
$5.9M
PCPT and SELECT cohorts: Core Infrastructure Support for Cancer Research UM1CA182883 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI TANGEN, CATHERINE M., THOMPSON, IAN M. · 2013 to 2017
$5.2M
Shanghai Men's Health StudyUM1CA173640 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SHU, XIAO-OU · 2013 to 2017
$4.9M
The NYU Women's Health StudyUM1CA182934 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZELENIUCH-JAQUOTTE, ANNE · 2015 to 2019
$3.7M
Established Investigator Award Anti-Inflammatory Exposures in Cancer PreventionK05CA154337 · NCI · UNIVERSITY OF WASHINGTON · PI WHITE, EMILY · 2011 to 2015
$637k
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS K05 CA154337NCI NIH HHS P50 CA102701NCI NIH HHS U10 CA037429NCI NIH HHS UG1 CA189974NCI NIH HHS UM1 CA173640NCI NIH HHS UM1 CA182883NCI NIH HHS UM1 CA182910NCI NIH HHS UM1 CA182934
6 · The paper itself

Abstract

Evidence on the association between vitamin D status and pancreatic cancer risk is inconsistent. This inconsistency may be partially attributable to variation in vitamin D regulating genes. We selected 11 vitamin D-related genes (GC, DHCR7, CYP2R1, VDR, CYP27B1, CYP24A1, CYP27A1, RXRA, CRP2, CASR and CUBN) totaling 213 single nucleotide polymorphisms (SNPs), and examined associations with pancreatic adenocarcinoma. Our study included 3,583 pancreatic cancer cases and 7,053 controls from the genome-wide association studies of pancreatic cancer PanScans-I-III. We used the Adaptive Joint Test and the Adaptive Rank Truncated Product statistic for pathway and gene analyses, and unconditional logistic regression for SNP analyses, adjusting for age, sex, study and population stratification. We examined effect modification by circulating vitamin D concentration (≤50, >50 nmol/L) for the most significant SNPs using a subset of cohort cases (n = 713) and controls (n = 878). The vitamin D metabolic pathway was not associated with pancreatic cancer risk (p = 0.830). Of the individual genes, none were associated with pancreatic cancer risk at a significance level of p<0.05. SNPs near the VDR (rs2239186), LRP2 (rs4668123), CYP24A1 (rs2762932), GC (rs2282679), and CUBN (rs1810205) genes were the top SNPs associated with pancreatic cancer (p-values 0.008-0.037), but none were statistically significant after adjusting for multiple comparisons. Associations between these SNPs and pancreatic cancer were not modified by circulating concentrations of vitamin D. These findings do not support an association between vitamin D-related genes and pancreatic cancer risk. Future research should explore other pathways through which vitamin D status might be associated with pancreatic cancer risk.

Indexed as

Genetic Predisposition to DiseaseBiomarkers, TumorCase-Control StudiesCohort StudiesFollow-Up StudiesGenotypeHumansMetabolic Networks and PathwaysPancreatic NeoplasmsPolymorphism, Single NucleotideRisk FactorsVitamin DVitamin D-Binding ProteinVitaminsBiomarkers, TumorVitamin DVitamin D-Binding ProteinVitamins

Identifiers

PMID25799011
PMCPMC4370655
OpenAlexW1967765404

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.